

To,
Corporate Relationship Department
National Stock Exchange of India Limited (NSE)
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400 051

Date-22.06.2026

Subject: Regulation 30 - SEBI (LODR) – Presentation to be made at the Analyst / Institutional Investors Meet with respect to Earning Call

We refer to our letter dated June 18, 2026 informing about the Earning Conference call on Tuesday, June 23, 2026 at 04:00 P.M (IST).

In this connection, we wish to inform you that the presentation to be made at the said meeting has been made available on the website of the Company.

No unpublished price sensitive information is proposed to be shared during the aforesaid meeting other than information already available in the public domain.

The audio/video recording and transcript of the meeting shall be disseminated to the Stock Exchange and uploaded on the Company's website within the timelines prescribed under the SEBI Listing Regulations.

You are requested to take the above information on record.

Thanking you,

For Q-LINE BIOTECH LIMITED

Saurabh Garg
Managing Director
DIN-02891621

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528



Spreading Healthiness!

Investor Presentation – H2 & FY26



Disclaimer

This presentation and the accompanying slides (the “Presentation”), has been prepared by **Q-line Biotech Limited** (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. The Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed.

H2 & FY26 Highlights





Saurabh Garg

Chairman &
Managing Director

“ FY26 has been a transformative year for Q-Line Biotech Limited. The successful capitalization of our largest manufacturing facility in Lucknow marks a significant milestone in our journey and substantially strengthens our manufacturing capabilities.

During the year, sales of manufactured reagents increased by nearly 70%, reflecting our strategic focus on expanding in-house manufacturing, improving value addition, and reducing dependence on traded products. We also achieved a key milestone in our instruments division, reaching an installed base of over 1,550 Selectra Pro M Fully Automatic Biochemistry Analysers, our flagship equipment product, whose manufacturing commenced in December 2023.

In addition, we successfully commercialized our Electrolyte Analyzer and are on track to launch the Micro lab 300 by Q2 FY27, further expanding and diversifying our diagnostic instruments portfolio. These achievements have strengthened our profitability profile, improved operating leverage, and reinforced our position in the diagnostics ecosystem.

As we continue to invest in manufacturing, innovation, and product development, we remain well-positioned to capitalize on the growing demand for high-quality diagnostic solutions and create long-term value for all stakeholders. ”



FY27 Guidance

Revenue Growth Target

~30 - 35% Y-o-Y

Key Developments Strengthening Long-Term Growth Drivers



Strong Recurring Revenue Base

Reagents **grew 35%** Y-o-Y and accounted for 69.8% of total revenue, supported by their consumable nature and strong recurring demand.



Margin Expansion

EBITDA margin improved from 22.5% to **28.7%**, supported by strong growth in high-margin domestically manufactured reagents, operating efficiencies, and favorable product mix.



Manufacturing Expansion

Unit 4, commissioned in February 2026, has obtained licenses for **five products**, with additional approvals under review. Commercial production of Clinical Chemistry Reagents is expected by Q2 FY27, subject to regulatory clearances.



International Expansion

Appointed Dubai-based International Business Manager and signed distributor agreements across **7-8 countries**. Export revenue reached Rs. 1.18 Cr in FY26, with exports expected to **grow ~5x** in FY27.



CDMO Opportunity

Planning to **commence CDMO operations** through manufacturing of Selectra Pro M and Microlab 300 instruments for export under an exclusive technical collaboration arrangement.



Digital Transformation

ERP implementation underway to strengthen process automation, operational controls, and data-driven decision-making; full rollout targeted by FY27-end.



Strengthening Governance

Engaged PwC to enhance **IFC and ICFR frameworks**, strengthening governance, risk management, and internal controls.



Strategic Technology Partnerships and Import Substitution


Exclusive partnerships with Vital Scientific and Boule Sweden AB have enabled localization of laboratory instrument and reagent manufacturing in India.

Over **50%** of laboratory equipment is now manufactured domestically, reducing import dependence, improving supply-chain resilience, and supporting higher margins.

Strong Growth with Significant Margin Expansion


Revenue (Rs. Lakhs)

CAGR: ▲ 23%




Gross Profit (Rs. Lakhs) & Margin (%)

CAGR: ▲ 30%




EBITDA (Rs. Lakhs) & Margin (%)

CAGR: ▲ 43%




PAT (Rs. Lakhs) & Margin (%)


CAGR: ▲ 20%




Net Worth (Rs. Lakhs)




Debt to Equity (x)



ROE (%)



ROCE (%)



Consolidated Profit & Loss – H2 & FY26

Particulars (Rs lakhs)	H2FY26	H2FY25	Y-o-Y	FY26	FY25	Y-o-Y
Net Revenue from Operations	19,794	21,655	-9%	34,174	31,314	9%
COGS	7,334	11,267		13,411	14,628	
Gross Profit	12,459	10,388	20%	20,763	16,686	24%
Gross Profit Margin (%)	62.9%	48.0%	1498 bps	60.8%	53.3%	747 bps
Employee Expenses	2,406	1,599		4,005	3,027	
Other Expenses	3,845	4,307		6,953	6,604	
EBITDA	6,208	4,482	39%	9,805	7,055	39%
EBITDA Margin (%)	31.4%	20.7%	1067 bps	28.7%	22.5%	616 bps
Other Income	303	852		570	883	
Depreciation	670	321		1,079	703	
Finance Cost	1,111	830		1,942	1,491	
PBT	4,730	4,183		7,354	5,743	
Extraordinary item & Prior Period Expense	-99	-1,962		-99	-2,270	
Share in P&L of associates	-	234		-	353	
Taxes	1,190	1,570		1,683	1,906	
PAT	3,441	884	289%	5,572	1,921	190%
PAT Margin (%)	17.4%	4.1%	1330 bps	16.3%	6.1%	1017 bps
EPS (Rs)	22.1	16.39		35.41	22.97	

Company Overview



Integrated IVD Platform with End-to-End Diagnostic Capabilities

- Q-Line Biotech is engaged in the **development, manufacturing, and marketing** of diagnostic reagents, kits, consumables, point-of-care (POC) devices, and diagnostic equipment.
- The Company serves **diagnostic laboratories, hospitals, and medical colleges** across India through a wide distribution network spanning 26 states.
- Leveraging its **manufacturing capabilities, R&D expertise, and strategic technology collaborations**, the company offers solutions across Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Rapid Testing segments.
- The Company is aligned with the Government of India's "**Make in India**" initiative, focusing on strengthening domestic capabilities.

Four Business Lines, One Diagnostic Ecosystem



Reagents (69.8%)

Core revenue driver. Recurring consumable demand from labs, hospitals, and diagnostic centres across India.



Diagnostic Instruments (24.3%)

Analyzers and automated testing machines for high-accuracy diagnostics in hospitals and reference labs. Mix of manufactured (Selectra Pro M) and traded instruments.



Consumables (5.1%)

Lab plasticware, macro cuvettes, tips, plates and other critical disposable items used in testing workflows.



Services (0.8%)

Annual maintenance contracts and technical support for the equipment base deployed with customers.

Operational Metrics

3+

Decades of Promoter Expertise

19

R&D Scientists & Engineers

4

Manufacturing Units

1

Instrument Commercialised

26

States & UT Served

7

Devices in Pipeline

362

Employees


15+

Registered Trademarks

International tie-ups: Technology Transfer Agreements with **Global Diagnostic Companies**

1. Reagents

- Essential Consumables used for **In vitro testing** (IVD) of human samples, supporting disease prediction, prevention, diagnosis, monitoring, and overall health status evaluation.
- Segment comprises of reagent kits, rapid cards, consumables & POC strips.



Test Categories Offered

Clinical Chemistry

Analyze chemical substances in bodily fluids, such as blood and urine.

Blood glucose tests for diabetes, liver and kidney function tests, and cholesterol.



Haematology

Test blood components, including red and white blood cells, platelets, and haemoglobin levels


Common test include CBC.



Immunodiagnosics

Widely used for diagnosing infections, autoimmune diseases, and allergies.

Examples include ELISA tests, rapid antigen tests, etc.



Molecular Diagnostics

Detecting genetic material (DNA or RNA) to diagnose infectious diseases, genetic disorders, and cancers.



Others

Microbiology tests, urinalysis, toxicology screenings, and point-of-care diagnostics.



2. Diagnostic Instruments

Diagnostic instruments

Diagnostic instruments, such as **analyser's and automated testing machines**, are critical of performing tests with high accuracy and efficiency.

With advancements in technology and automation, this segment is witnessing steady growth, particularly in hospitals, laboratories, and diagnostic centres.

Manufacturing & Trading

Manufacturing and trading of essential devices used in clinical diagnostics and healthcare settings.


Products include analyzers, point-of-care devices, and other critical components. Currently manufacturing instrument analyzers used in clinical chemistry.

Selectra Pro M (Made in India)

Fully automatic clinical chemistry analyzer with technical collaboration with European company

Successfully scaled up for commercial production and is already serving laboratories across multiple regions.

Break up of Diagnostic Instrument Business
(Rs. in Lakhs)



PRODUCT PORTFOLIO SHOWCASE



Hemoglo Analyzer

The Fully automated HbA1c (HPLC)



ASTIRA CX4000

Fully Auto-Chemistry Analyzer



Selectra Pro M Lite

Automated biochemistry



Medonic M32

3 Parts cell counter | Haematology analyzer

Diagnostic Instruments – Under Development

A deep development roadmap expected to materially expand Q-Line's product portfolio and total addressable market, **aligned with the Make in India initiative**



Clinical Analyzers

Selectra Pro XL

Fully automatic clinical chemistry analyser designed for large laboratories and hospital networks.

Mircolab 300

Semi-automatic clinical chemistry analyser



Haematology Analyzer

Medonic M20

Prototype completed in collaboration with European company. **Undergoing regulatory review.**

Q-Count 5

Indigenous 5-part haematology analyser.

Under development



Coagulation Analyzer

KC1 Del

Developed in technical partnership with Stago.

Prototype under regulatory review.



Electrolyte Analyzer and an Automated Slide Stainer

InnoLyte electrolyte analyser and an automated slide stainer

Indigenously developed


3. Consumables and Service



Consumables

Variety of consumables are utilized in diagnostic tests and procedures, some of which are critical, including Macro Cuvettes with Balls, Lab Plastic Plates, Laboratory Plastic Tip Rack, Syringe Pump, and others.


Revenue (Rs. Lakhs)



Services

This includes the annual maintenance of the medical equipment's that we sell to our customers

Revenue (Rs. Lakhs)



Competitive Advantages Supporting Sustainable Growth



Integrated IVD Platform

End-to-end capabilities spanning reagent development, instrument manufacturing, and consumables, a rare combination in the Indian IVD market that creates a durable competitive moat and cross-sell opportunities.

01



International Technology Tie-Ups

Technology transfer agreements with global diagnostic companies, including **European partnerships** for the Selectra Pro M analyser and Medonic haematology platforms, bringing world-class specs to India's price points.

02



Make-in-India Pioneer

One instrument already commercialized, **seven devices under development.** Perfectly aligned with PLI Scheme tailwinds, reducing import dependency across India's fast-growing diagnostics sector.

03



R&D Division

19 scientists and engineers driving reverse engineering, new formulation development, and instrument innovation. R&D spend maintained at ~1% of revenue, focused on high-impact projects.

04



Experienced Leadership

Chairman & MD Saurabh Garg brings **31+ years** in healthcare and diagnostics. The full leadership team averages over 25 years of sector experience — giving the company deep institutional knowledge and long-standing customer trust.

05



Pan-India Distribution Reach

Present across **26 states and 2 UTs.** Revenue heavily anchored in North India with Uttar Pradesh contributing ~77%, while systematic geographic diversification is underway across South, East and West zones.

06









CDMO Opportunity

Positioning as a full-service **CMO/CDMO for IVD**, enabling both domestic innovators and international players to leverage India's manufacturing cost advantage. Already serving three EOL component clients.

07

State-of-the-Art Manufacturing Facilities

 Manufacturing Facility	Unit 1	Unit 2	Unit 3	Unit 4
 Location	Delhi	Lucknow	Lucknow	Lucknow
 Commencement Year	May 2016	December 2023	December 2023	February 2026
 Products Manufactured	Clinical Chemistry, Molecular Reagents & Rapid-Elisa Kits	Hematology Reagents	Clinical Chemistry Instrument	Clinical, Rapid, POC Reagents & POC Devices
 Installed Capacity	1.27 Mn Kits	96,000 Kits	1,200 Analyzers	75.5 Mn Rapid-ELISA Kits 93.6 Mn Glucometer Strips 1.5 Mn Clinical Chemistry Reagents 31,200 Glucometer Device
 FY26 Utilization	79%	67%	57%	Newly Commissioned

Regulatory Compliance

All facilities are subject to regular inspections and audits by CDSCO, State Drug Authorities, Intertek, URS Certification Limited and other European regulatory agencies.




Diversified Geographic Presence

Nationwide Reach. Growing Every Year.

From government hospitals to reference labs, Q-Line products are embedded across India's diagnostic infrastructure, with export initiatives now extending to Africa, the Middle East and the Indian sub-continent

Zonal Wise Revenue Breakup %



Experienced Leadership Team



**SAURABH
GARG**

Chairman &
Managing Director

Experience:

30+ years

Qualification:

Diploma in
Electronics
Engineering



**AYUSH
GARG**

Non-Executive Director

Experience:

5+ years

Qualification:

Bachelor of
Science



**YETHADKA SUBRAYA
PRABHAKARA**

Whole Time Director

Experience:

30+ years

Qualification:

GDM from IIM-
Ahmedabad



**KULDEEP
CHOWDHRY**

Whole Time Director

Experience:

25+ years

Qualification:

Master of
Business
Administration &
Bachelor of
Science



**AJAY KUMAR
MAHANTY**

CEO

Experience:

20+ years

Qualification:

Master of
Business
Administration &
Bachelor of
Science



**MEENAL
GUPTA**

CFO

Experience:

18+ years

Qualification:

Qualified
Chartered
Accountant

Roadmap for Scale, Diversification and Global Expansion

Scale manufacturing – Make in India

Grow manufacturing and production capacity aligned with the Government of India's **"Make in India"** initiative. The Company has recently completed capex for its 4th manufacturing unit, significantly boosting capacity with a focus on reagents and the growing CDMO business.

Expand the product portfolio

Additional formulations in reagents and increased diversification in consumables. Entering new instrument categories – **Immunodiagnosics, Clinical Chemistry, and Haematology.**



Deepen and widen market reach

Target **Key Account Sales** through Corporate Lab Chains in existing markets, alongside international expansion into the **African Union, Middle East, and Indian sub-continent regions.**

Build CMO/CDMO alliances

Positioning as a full-service CMO/CDMO for IVD, enabling domestic innovators and international players to capitalize on India's dynamic market. Already **reduced costs and sourced EOL components for three clients.**



Strategy in numbers



4th
Manufacturing unit live



3
New instrument categories



3
New export region



3
CDMO clients served

Industry Overview



In-Vitro Diagnostics (IVD) serves as a **critical component** of the healthcare infrastructure, **facilitating early disease detection and accurate diagnosis.**

Regulatory Process

Manufacturers must obtain **CDSCO** approval before marketing, submitting clinical data and specifications, with stricter norms for higher-risk classes. Approval process for IVD devices is lengthy and complex due to stringent safety regulations,



Post-Market Surveillance and Compliance

Manufacturers must implement post-market surveillance to track the performance of IVD devices



Supply Chain Disruptions


Market is dependent on global supply chain for raw materials, manufacturing components, and distribution



IVD Industry Landscape (1/3)

In-Vitro Diagnostics (IVD) serves as a **critical component** of the healthcare infrastructure, **facilitating early disease detection and accurate diagnosis**. Rising burden of **chronic diseases** (diabetes, cardiovascular diseases, cancer) and **infectious diseases** (tuberculosis, dengue, COVID-19) is a key driver of **IVD demand**. IVD industry is poised for steady growth, fueled by technological innovations, growing geriatric populations, cost-efficient solutions, and increased adoption.

India's IVD Market Growth Story (Mn USD)




Market Segmentation By Products – IVD Industry (2/3)

REAGENTS & KITS

Holds the largest pie share, this dominance is driven by the recurring demand for consumables used in diagnostic tests.

Demand Driver:

Increasing prevalence of diseases and growing adoption of point-of-care testing.



Market Share by Product Type - CY25

DIAGNOSTIC EQUIPMENT

Includes Analyzers & Automated testing machines, critical for performing tests with high accuracy.

Demand Driver:

Advancements in technology and automation.


SERVICES

Software solutions for result interpretation along with maintenance and support services for IVD instruments.

Demand Driver:

Digital health solutions, artificial intelligence, and data analytics.

Market Segmentation By End User Usability - IVD Industry (3/3)



- Hospitals Laboratories
- Clinical Laboratories
- Point-of-care Testing Centers
- Patient Self-Testing
- Academic Institutes
- Others

Market Share by Application Usability - CY25



Hospital laboratories:

Which constitute 38% of the market in CY25, underscoring their critical role in diagnostic services for a wide range of medical conditions.



Clinical laboratories:

Clinical laboratories follow closely, accounting for 30% of the market, driven by their extensive use in routine and specialized testing.



Point-of-care testing centres:

Represent 13% of the market, highlighting the growing demand for decentralized and rapid diagnostic solutions.



Patient self-testing:

Holds a 10% share, reflecting the increasing preference for home-based diagnostics



Academic institutes:

and other segments, comprising 4% and 5% respectively, contribute to research and specialized testing.



As India's population grows and life expectancy increases, the demand for diagnostic solutions continues to rise.

Government Initiatives:



Production-Linked Incentive (PLI) Scheme:

Incentives to manufacturers producing high-end diagnostic kits, reagents, and analyzers reducing reliance on imports.



National Healthcare Mission & Ayushman Bharat:

Expands diagnostic access in rural areas by upgrading health centers and labs, integrating advanced diagnostic tools.



ICMR Support for Diagnostic Innovation:

The Indian Council of Medical Research (ICMR) has played a key role in advancing the IVD sector by supporting the development and validation of indigenous & making high-quality testing accessible.

Promising future:

- Advancements in diagnostic technologies
- Surge in investments and R&D in diagnostics, fostering innovation.



Annual Financials



Consolidated Profit & Loss Statement

Particulars (Rs lakhs)	FY23*	FY24*	FY25	FY26	CAGR
Net Revenue from Operations	18,274	20,365	31,314	34,174	23%
COGS	8,847	9,302	14,628	13,411	
Gross Profit	9,427	11,063	16,686	20,763	30%
Gross Profit Margin (%)	51.6%	54.3%	53.3%	60.8%	
Employee Expenses	2,368	2,349	3,027	4,005	
Other Expenses	3,689	4,914	6,604	6,953	
EBITDA	3,370	3,800	7,055	9,805	43%
EBITDA Margin (%)	18.4%	18.7%	22.5%	28.7%	
Other Income	208	280	883	570	
Depreciation	214	393	703	1,079	
Finance Cost	380	628	1,491	1,942	
PBT	2,984	3,060	5,743	7,354	
Extraordinary item & Prior Period Expense	-	-	-2,270	-99	
Share in P&L of associates	1,071	1,280	353	-	
Tax Expense	846	896	1,906	1,683	
PAT	3,210	3,444	1,921	5,572	20%
PAT %	17.6%	16.9%	6.1%	16.3%	
EPS (Rs)	20.38	21.87	22.97	35.41	

Note: *FY23 and FY24 are Restated Numbers

Consolidated Balance Sheet

Equity & Liabilities (Rs lakhs)	Mar-23*	Mar-24*	Mar-25	Mar-26
Share Capital	158	158	158	1,628
Reserves & Surplus	12,579	16,024	18,838	22,992
Minority Interest	-	-	-	-
Shareholders' Funds	12,737	16,181	18,995	24,619
Long Term Borrowings	1,431	3,509	8,241	9,619
Long Term Provisions	166	186	262	439
Other Non-Current Liabilities	10	20	137	199
Total Non-Current Liabilities	1,607	3,715	8,640	10,258
Short Term Borrowings	5,934	6,182	8,254	12,929
Trades Payable	3,971	5,924	5,562	5,204
Other Current Liabilities	613	1,664	2,498	2,248
Short Term Provisions	297	258	1,600	610
Total Current Liabilities	10,815	14,028	17,914	20,992
Total Equity and Liabilities	25,158	33,925	45,550	55,869

Assets (Rs lakhs)	Mar-23*	Mar-24*	Mar-25	Mar-26
Property, Plant & Equipment and Intangible Assets	2,280	5,992	7,364	14,158
Capital Works-in-Progress	1,174	1,917	6,255	1,931
Other Non-Current Assets	4,093	6,162	5,466	5,374
Total Non-Current Assets	7,547	14,071	19,086	21,463
Inventories	4,359	10,524	9,021	9,496
Trade Receivables	3,306	2,644	8,260	12,582
Cash and Cash Equivalents	9,002	2,996	4,703	7,644
Short-Term Loans and Advances	934	3,673	3,258	3,657
Other Current Assets	10	16	1,222	1,026
Total Current Assets	17,611	19,853	26,464	34,406
Total Assets	25,158	33,925	45,549	55,869

Note: *FY23 and FY24 are Restated Numbers

Initial Public Offering

IPO Details

The company was successfully listed on NSE (SME platform) on **29th May 2026**

Raised **Rs. 214.48 crores** through a fresh issuance of 62,53,000 equity shares


Utilization Proceeds:

✓ Working Capital requirements

✓ Repayment of Borrowings

✓ General Corporate Purposes

Shareholding Pattern (%)



■ Promoters ■ FIIs ■ DII ■ Public



Thank You



Q-line Biotech Limited


 Meenal Gupta - CFO


 meenal.gupta@pocservices.com


 005 222 435570



Stellar IR Advisors Pvt Ltd

 Ankit Jain

 ankit@stellar-ir.com

 +91 22 62398024

